We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CTLT
126
DELISTED
CATALENT, INC.
CTLT
$2.45M 0.05%
47,100
+12,800
+37% +$699K
SYNH
127
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$2.44M 0.05%
61,900
+16,300
+36% +$953K
LH icon
128
Labcorp
LH
$24.3B
$2.26M 0.04%
20,790
+14,358
+223% +$2.07M
SRPT icon
129
Sarepta Therapeutics
SRPT
$1.66B
$1.96M 0.04%
20,000
+4,500
+29% +$514K
XLRN
130
DELISTED
Acceleron Pharma
XLRN
$1.95M 0.04%
21,700
-2,500
-10% -$194K
ABBV icon
131
AbbVie
ABBV
$458B
$1.94M 0.04%
25,400
-17,100
-40% -$1.46M
MNTA
132
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$1.83M 0.04%
67,400
-95,000
-58% -$2.64M
ACAD icon
133
Acadia Pharmaceuticals
ACAD
$4.25B
$1.77M 0.03%
42,000
+2,000
+5% +$82.4K
QURE icon
134
uniQure
QURE
$2.68B
$1.5M 0.03%
31,500
+2,600
+9% +$149K
QTNT
135
DELISTED
Quotient Limited Ordinary Shares
QTNT
$1.41M 0.03%
8,897
– –
ASND icon
136
Ascendis Pharma A/S
ASND
$16.7B
$1.34M 0.03%
+11,900
New +$1.55M
RGEN icon
137
Repligen
RGEN
$7.44B
$1.31M 0.03%
13,600
– –
KYNB
138
Kyntra Bio
KYNB
$28.5M
$1.31M 0.03%
1,504
-36
-2% -$35.8K
MRTX
139
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.22M 0.02%
15,900
-400
-2% -$35.9K
RGNX icon
140
Regenxbio
RGNX
$623M
$1.2M 0.02%
36,900
+16,000
+77% +$667K
PRGO icon
141
Perrigo
PRGO
$1.4B
$981K 0.02%
+20,400
New +$1.09M
RARE icon
142
Ultragenyx Pharmaceutical
RARE
$2.65B
$955K 0.02%
+21,500
New +$1.12M
BLUE
143
DELISTED
bluebird bio
BLUE
$910K 0.02%
1,529
+116
+8% +$113K
BHVN
144
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$844K 0.02%
24,800
+2,100
+9% +$96K
APLS
145
DELISTED
Apellis Pharmaceuticals
APLS
$801K 0.02%
+29,900
New +$1.06M
CHRS icon
146
Coherus Oncology
CHRS
$217M
$787K 0.02%
48,500
-100,000
-67% -$1.85M
YI
147
111 Inc
YI
$763K 0.01%
+11,543
New +$735K
CLLS
148
Cellectis
CLLS
$286M
$693K 0.01%
+75,300
New +$1.12M
ZYME icon
149
Zymeworks
ZYME
$1.68B
$653K 0.01%
+18,400
New +$753K
DPZ icon
150
Domino's
DPZ
$11B
$616K 0.01%
1,900
– –
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.